Canaan reels in a jum­bo $800M fund with a big fo­cus on a new wave of biotech star­tups

In the lat­est sign of the leviathan ap­petite ven­ture in­vestors have for new tech­nol­o­gy, Canaan Part­ners — one of the busiest play­ers in biotech — has raised a firm-record $800 mil­lion fund to dri­ve a new wave of bets in the biz.

The Sil­i­con Val­ley-based Canaan has many in­ter­ests — fin­tech, mar­ket­places, en­ter­prise — with a spe­cial place in the port­fo­lio for a big chunk of bio­phar­ma. Known as a reg­u­lar in seed fi­nanc­ings and Se­ries A rounds, Canaan likes to get in ear­ly.

Canaan al­so likes to make mon­ey, which has been helped with 30 ex­its over the past 3 years. Nine of those were from the biotech port­fo­lio. The lim­it­ed part­ners have been good in re­turn; the last fund Canaan raised rang in at $675 mil­lion.

Tim Shan­non

Tim Shan­non, the East Coast gen­er­al part­ner and an ex­pe­ri­enced biotech vet who’s cur­rent­ly work­ing with a slate of com­pa­nies that in­cludes Arv­inas and IDEAYA, is ready to roll.

There are a num­ber of ear­ly-stage in­vestors that Canaan likes to work with, he says. Once their com­pa­nies hit Phase I, says Shan­non, they pre­fer to in­vest in ar­eas where they know they have a good chance of suc­cess. So ge­net­ic val­i­da­tion is im­por­tant for de-risk­ing their work. An­ti-in­fec­tives have been a hall­mark of their work.

But aside from the big­ger num­bers in Fund XI, adds Shan­non, not much changes.

“I think we’ll keep our same phi­los­o­phy in terms of the kinds of in­vest­ments we’re tar­get­ing,” he says. Then he ticks them off: “Ear­ly-stage, trans­for­ma­tive, high own­er­ship, high re­turns.”

You can fig­ure about 40% of the fund will go to health­care, rough­ly $360 mil­lion. Of that, look for about 75% to go in­to bio­phar­ma af­ter “di­al­ing up a notch” in the in­dus­try. That will trans­late in­to about 15 new com­pa­nies — plat­forms are a key — with about $15 mil­lion or so for each. A good rule of thumb is that 60% will be­come suc­cess­ful ex­its. Break it down fur­ther, he says, and 20% will be fund mak­ers, 20% will con­tribute, 20% will get by.

What’s not on Canaan’s plate? Com­mon dis­eases are tough to crack, says Shan­non. Di­a­betes and car­dio are two prime ex­am­ples, where ge­net­ic val­i­da­tion is of­ten lack­ing. PC­SK9 could have been a break­through, he notes, but it hasn’t fired up yet.

That ba­sic phi­los­o­phy, trans­lat­ed by a small team of pro­fes­sion­als, has paid off con­sis­tent­ly for the past 10 years.

In a blog post out to­day, the VC un­der­scored the val­ue of di­ver­si­ty and col­lab­o­ra­tion:

It may sound trite, but hav­ing a “no ass­holes pol­i­cy” works. Ours is a team-ori­ent­ed, trans­par­ent and col­lab­o­ra­tive cul­ture, with a com­pen­sa­tion struc­ture that re­wards per­for­mance — re­gard­less of a team mem­ber’s tenure. Sil­i­con Val­ley, in par­tic­u­lar, has seen the im­pact of un­der­rep­re­sen­ta­tion in gut-wrench­ing ways over the past few weeks. We know that hav­ing more points of view at the ta­ble makes a dif­fer­ence and we lead by ex­am­ple, with an in­vest­ment team that is 40% women — in­clud­ing at the Gen­er­al Part­ner lev­el — and 47% im­mi­grant or first-gen­er­a­tion.

Qual­i­ty Con­trol in Cell and Gene Ther­a­py – What’s Re­al­ly at Stake?

In early 2021, Bluebird Bio was forced to suspend clinical trials of its gene therapy for sickle cell disease after two patients in the trial developed cancer. As company scientists rushed to assess whether there was any causal link between the therapy and the cancer cases, Bluebird’s stock value plummeted – as did those of multiple other biopharma companies developing similar therapies.

While investigations concluded that the gene therapy was unlikely to have caused cancer, investors and the public may be more skittish regarding the safety of gene and cell therapies after this episode. This recent example highlights how delicate the fields of cell and gene therapy remain today, even as they show great promise.

Brad Bolzon (Versant)

Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed

Brad Bolzon has an apology to offer by way of introducing a set of 3 new funds that together pack a $950 million wallop in new biotech creation and growth.

“I want to apologize,” says the Versant chairman and managing partner, laughing a little in the intro, “that we don’t have anything fancy or flashy to tell you about our new fund. Same team, around the same amount of capital, same investment strategy. If it ain’t broke, don’t fix it.”

But then there’s the flip side, where everything has changed. Or at least speeded into a relative blur. Here’s Bolzon:

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Law pro­fes­sors call for FDA to dis­close all safe­ty and ef­fi­ca­cy da­ta for drugs

Back in early 2018 when Scott Gottlieb led the FDA, there was a moment when the agency seemed poised to release redacted complete response letters and other previously undisclosed data. But that initiative never gained steam.

Now, a growing chorus of researchers are finding that a dearth of public data on clinical trials and pharmaceuticals means industry and the FDA cannot be held accountable, two law professors from Yale and New York University write in an article published Wednesday in the California Law Review.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Novavax CEO Stanley Erck at the White House in 2020 (Andrew Harnik, AP Images)

As fears mount over J&J and As­traZeneca, No­vavax en­ters a shaky spot­light

As concerns rise around the J&J and AstraZeneca vaccines, global attention is increasingly turning to the little, 33-year-old, productless, bankruptcy-flirting biotech that could: Novavax.

In the now 16-month race to develop and deploy Covid-19 vaccines, Novavax has at times seemed like the pandemic’s most unsuspecting frontrunner and at times like an overhyped also-ran. Although they started the pandemic with only enough cash to last 6 months, they leveraged old connections and believers into $2 billion and emerged last summer with data experts said surpassed Pfizer and Moderna. They unveiled plans to quickly scale to 2 billion doses. Then they couldn’t even make enough material to run their US trial and watched four other companies beat them to the finish line.

FDA of­fers scathing re­view of Emer­gent plan­t's san­i­tary con­di­tions, em­ploy­ee train­ing af­ter halt­ing pro­duc­tion

The FDA wrapped up its inspection of Emergent’s troubled vaccine manufacturing plant in Baltimore on Tuesday, after halting production there on Monday. By Wednesday morning, the agency already released a series of scathing observations on the cross contamination, sanitary issues and lack of staff training that caused the contract manufacturer to dispose of millions of AstraZeneca and J&J vaccine doses.

Jenny Rooke (Genoa Ventures)

Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem

When Jenny Rooke first heard of Zymergen back in 2014, she knew she was looking at something different and exciting. The Emeryville, CA biotech held the promise of blending biology and technology to solve a huge unmet need for cost-effective chemicals — of all things — and a stellar founding team to boot.

But back then, West Coast venture capitalists didn’t see in Zymergen the one thing they were looking for in a winning biotech: therapeutic potential. Rooke, however, saw an opportunity and made her bets. Seven years later, that bet is paying off in a big way.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.

Saurabh Saha at Endpoints News' #BIO19

On the heels of $250M launch, Centes­sa barges ahead with an IPO to fu­el its 10-in-1 Medicxi pipeline

Francesco De Rubertis made no secret of IPO plans for Centessa, his 10-in-1 legacy play. Barely two months later, the S-1 is in.

The hot-off-the-press filing depicts the same grand vision that the longtime VC touted when he did the rounds in February: Take the asset-centric mindset that he’s been preaching at Medicxi over the years, and roll up a bunch of biotech upstarts, with unrelated risk profiles, into 1 pharma company that can carry on the development at scale.

Sen. Patty Murray (D-WA) (Graeme Sloan/Sipa USA/Sipa via AP Images)

Sen­a­tors to NIH: Do more to pro­tect US bio­med­ical re­search from for­eign in­flu­ence

Although Thursday’s Senate health committee hearing was focused on how foreign countries and adversaries might be trying to steal or negatively influence biomedical research in the US, the only country mentioned by the senators and expert witnesses was China.

Committee chair Patty Murray (D-WA) made clear in her opening remarks that the US cannot “let the few instances of bad actors” overshadow the hard work of the many immigrant researchers in the US, many of which have won Nobel prizes for their work. But she also said, “There is more the NIH can be doing here.”

Steffen Schuster, ITM CEO

Ra­dio­phar­ma re­mains hot as Ger­many's ITM rais­es $109M to ad­vance neu­roen­docrine can­cer pro­gram

The world of radiopharmaceuticals has been heating up over the last few years, and Thursday saw another company focused on the field pull in a new nine-figure raise.

Germany’s ITM, or Isotopen Technologien München, scored a $109 million round of loan financing to push forward its precision oncology pipeline and fund late-stage development for its lead program. As part of the agreement, the loan will convert to shares in the event of future financial or corporate transactions, ITM said.